Dr. Martens (LON:DOCS) Given “Buy” Rating at Berenberg Bank

Posted by on May 6th, 2026

Dr. Martens (LON:DOCS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Berenberg Bank in a research note issued to investors on Wednesday,Digital Look reports. They currently have a GBX 114 price target on the stock. Berenberg Bank’s price target suggests a potential upside of 76.74% from the stock’s current price.

Separately, Royal Bank Of Canada restated a “sector perform” rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 3,057.

Get Our Latest Report on DOCS

Dr. Martens Trading Up 3.9%

LON:DOCS opened at GBX 64.50 on Wednesday. Dr. Martens has a one year low of GBX 52.50 and a one year high of GBX 100.87. The company has a debt-to-equity ratio of 120.66, a quick ratio of 1.13 and a current ratio of 2.18. The firm has a market cap of £623.55 million, a P/E ratio of 37.94, a P/E/G ratio of 6.40 and a beta of 0.24. The firm has a 50-day simple moving average of GBX 64.79 and a 200-day simple moving average of GBX 73.36.

Insider Activity

In other news, insider Ije Nwokori sold 204,051 shares of Dr. Martens stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of GBX 66, for a total value of £134,673.66. Over the last quarter, insiders have purchased 902 shares of company stock valued at $60,382. 2.81% of the stock is owned by insiders.

About Dr. Martens

(Get Free Report)

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.

See Also

Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.